Preprint Review Version 1 This version is not peer-reviewed

The Role of Chemerin in Upper Gastrointestinal Cancer

Version 1 : Received: 12 September 2024 / Approved: 13 September 2024 / Online: 13 September 2024 (04:30:17 CEST)

How to cite: Mylonakis, A.; Frountzas, M.; Lidoriki, I.; Kozadinos, A.; Kalfoutzou, A.; Karanikki, E.; Tsikrikou, I.; Kyriakidou, M.; Theodorou, D.; Toutouzas, K. G.; Schizas, D. The Role of Chemerin in Upper Gastrointestinal Cancer. Preprints 2024, 2024091050. https://doi.org/10.20944/preprints202409.1050.v1 Mylonakis, A.; Frountzas, M.; Lidoriki, I.; Kozadinos, A.; Kalfoutzou, A.; Karanikki, E.; Tsikrikou, I.; Kyriakidou, M.; Theodorou, D.; Toutouzas, K. G.; Schizas, D. The Role of Chemerin in Upper Gastrointestinal Cancer. Preprints 2024, 2024091050. https://doi.org/10.20944/preprints202409.1050.v1

Abstract

Background/Objectives: Chemerin, which is a multifunctional cytokine and adipokine, has been implicated in inflammatory and metabolic processes and might play a role in upper gastrointes-tinal (GI) malignancies, particularly gastric and esophageal cancer. The aim of this review is to explore the role of chemerin in the pathophysiology of upper GI cancers, as well as its potential as a biomarker for early detection and as a therapeutic target. Methods: A comprehensive review of recent studies about chemerin's biochemical properties and interaction with its receptors, as well as its effects on inflammatory responses, immune regulation and metabolic processes was con-ducted. Clinical implications of chemerin on gastric and esophageal cancer were analyzed, whereas the potential therapeutic strategies targeting chemerin were discussed. Results: Elevated chemerin levels are associated with poor prognosis in gastric cancer and promote invasiveness and metastasis in esophageal cancer. Chemerin receptor antagonists show promising results in inhibiting cancer cell migration, invasion and progression. Conclusions: Chemerin could repre-sent a valuable prognostic biomarker and therapeutic target for upper GI cancers. Future observa-tional studies should validate its clinical applications and investigate the efficacy of chemerin in-hibitors as potential therapeutic targets.

Keywords

Chemerin; Gastric cancer; Esophageal cancer; Obesity; Biomarker

Subject

Medicine and Pharmacology, Endocrinology and Metabolism

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.